5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted therapy in advanced bladder cancer: What have we learned?
    Journal Article

    Jordan, E. J.; Iyer, G.
    Urologic Clinics of North America (2015)

    Fulltext@MSK | Save
  • Genomic characterization of upper tract urothelial carcinoma
    Journal Article

    Sfakianos, J. P.; Cha, E. K.; Iyer, G.; Scott, S. N.; Zabor, E. C.; Shah, R. H.; Ren, Q.; Bagrodia, A.; Kim, P. H.; Hakimi, A. A.; more...
    European Urology (2015)

    Fulltext@MSK | Save
  • Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN plus EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R.; Hutson, T.; Glen, H.; Michaelson, M. D.; Molina, A.; Eisen, T.; Jassem, J.; Zolnierek, J.; Maroto, P.; Mellado, B.; more...
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E.; Rini, B.; Bhatt, R. S.; Alter, R.; Beck, J. T.; Mutyaba, M.; Pappas, K.; Wilson, D.; Zhang, X.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E.; Rini, B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K.; Wilson, D.; Zhang, X.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • CheckMate 025: A randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Escudier, B.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC)
    Meeting Abstract

    Knox, J. J.; Barrios, C. H.; Kim, T. M.; Cosgriff, T.; Srimuninnimit, V.; Pittman, K.; Sabbatini, R.; Rha, S. Y.; Flaig, T. W.; Page, R. D.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next-generation sequencing (NGS): Results from RECORD-3
    Meeting Abstract

    Hsieh, J. J.; Chen, D.; Wang, P. I.; Chen, Y. B.; Redzematovic, A.; Marker, M.; Patel, P.; Chevinsky, M.; Bhanot, U.; Pinciroli, P.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Expanded cohort results from CheckMate 016: A Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Hammers, H. J.; Plimack, E. R.; Lnfante, J. R.; Rini, B. I.; McDermott, D. F.; Ernstoff, M. S.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) who were treated beyond progression in a randomized phase 2 dose-ranging trial
    Meeting Abstract

    George, S. B.; Motzer, R. J.; Hammers, H.; Redman, B.; Kuzel, T.; Tykodi, S. S.; Plimack, E.; Jiang, L. J.; Waxman, L.; Rini, B. I.
    BJU International (2015)

    Fulltext@MSK | Save